Nasdaq · Healthcare
TransMedics Group, Inc. (TMDX)
As-reported financials and recent SEC filings for TransMedics Group, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$605.5M
Net income
$190.3M
Net margin
31.4%
Diluted EPS
$4.87
ROE
40.2%
P/E (TTM)
15.7×
Market cap
$2.37B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M |
| Gross profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M |
| Operating income | $108.6M | $37.5M | $-28.7M | $-31.4M | $-39.4M |
| Net income | $190.3M | $35.5M | $-25.0M | $-36.2M | $-44.2M |
| Diluted EPS | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →SD2026-05-29
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →Go deeper on TMDX
Search TransMedics Group, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.